Two decades of composite expertise, and a medical company setting sail since 2020.
The Group's automotive interior composite segment started more than two decades ago, focusing on composite fabric R&D and manufacturing, gradually growing into a supplier for mainstream Chinese automotive brands — laying a solid composite-process foundation for the future entry into healthcare.
The automotive segment expanded to 5 composite plants nationwide, with annual output exceeding 30 million meters and a 30% market share. Beyond composite fabrics, the segment independently develops and manufactures China's leading lamination equipment, files multiple patents each year, and is recognized as a "High-tech", "Specialized & Innovative", and "Little Giant" enterprise.
Jinzhida Medical Devices (Shanghai) Co., Ltd. was established in Jiading, Shanghai, as the Group's core medical enterprise — an industry-trade integrated company combining R&D, manufacturing and sales, formally entering the medical device field with a focus on wound healing promotion.
The Group completed the integration of three business segments — automotive interior composites, medical devices and testing services — with 9 subsidiaries and headquarters in Jiading, Shanghai, entering a new stage of scaled development.
Class 10,000 and Class 100,000 standardized clean production workshops were put into operation, together with a professional R&D laboratory. Multiple automated production lines went live, with all processes strictly governed by the ISO 13485 medical device quality management system.
Based on international wound care concepts, we built the DIMES five-in-one wound management system (Debridement · Infection · Moisture · Edge · Support), forming a product landscape of "core business + full-category coverage".
The product line extended from core dressings into seven series — home healthcare, rehabilitation, basic consumables, portable diagnostics, maternal & infant health, emergency / OR supplies, and dental products — with mature OEM / ODM capabilities covering specifications, formulations, packaging and appearance.
Group revenue reached CNY 1 billion. The medical company formally launched its internationalization strategy with an official store on Alibaba.com. Multiple core products obtained EU CE and US FDA certifications, with overseas shipments becoming a regular occurrence.
Deepening overseas OEM / ODM cooperation, an expanding overseas customer base, and a steadily growing global distribution and cooperation network — striving to become a trusted professional wound care brand and a one-stop medical device partner worldwide.
